TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25005651

Group type: EXPERIMENTAL
Intervention: Postoperative antibiotic treatment with amoxicillin plus clavulanic acid (2 g, 3 times a day for 5 days)
Number of subjects: 414

Group type: COMPARATOR
Intervention: No postoperative antibiotics (nontreatment group)
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Both groups (antibiotic and nontreatment)
Number of subjects: 414
Study: 22681960

Group type: COMPARATOR
Intervention: Intravenous esomeprazole
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Oral lansoprazole
Number of subjects: 100
Study: 20929937

Group type: EXPERIMENTAL
Intervention: Medial suture placement in torn tendons
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lateral suture placement in intact tendons
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lateral suture placement in torn tendons
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medial suture placement in intact and torn tendons
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lateral region in torn specimens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lateral region in intact specimens
Number of subjects: 0
Study: 17974932

Group type: EXPERIMENTAL
Intervention: Self-management cognitive behavior therapy
Number of subjects: 45

Group type: COMPARATOR
Intervention: Supportive counseling
Number of subjects: 45
Study: 16387596

Group type: EXPERIMENTAL
Intervention: Omalizumab (0.016 mg/kg/IgE [IU/mL]/mo) plus immunotherapy
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Omalizumab plus immunotherapy
Number of subjects: 159

Group type: COMPARATOR
Intervention: Placebo plus immunotherapy
Number of subjects: 159
Study: 11891449

Group type: EXPERIMENTAL
Intervention: Unilateral laminectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conservative therapy
Number of subjects: 0
Study: 9860243

Group type: EXPERIMENTAL
Intervention: Skin application food test (SAFT)
Number of subjects: 0
Study: 8106625

Group type: EXPERIMENTAL
Intervention: RU 486 (200 mg/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 2802540

Group type: EXPERIMENTAL
Intervention: Physostigmine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31061282

Group type: EXPERIMENTAL
Intervention: Na restriction (NaCl: 6 g/d)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (NaCl: 12 g/d)
Number of subjects: 11
Study: 28676251

Group type: EXPERIMENTAL
Intervention: Combined oral contraceptives (COC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Free cycling women
Number of subjects: 0
Study: 25403027

Group type: EXPERIMENTAL
Intervention: Culturally sensitive empowerment group intervention (Nia)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 89
Study: 23912197

Group type: COMPARATOR
Intervention: Dry needling
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Dry needling combined with autologous conditioned plasma (ACP) injection
Number of subjects: 28
Study: 21838845

Group type: EXPERIMENTAL
Intervention: CRA plus vouchers
Number of subjects: 58

Group type: COMPARATOR
Intervention: CRA
Number of subjects: 58
Study: 19663128

Group type: EXPERIMENTAL
Intervention: Purified extract VIT (group A, 44 patients)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Nonpurified extract VIT (group B, 50 patients)
Number of subjects: 94
Study: 16455438

Group type: EXPERIMENTAL
Intervention: Hand moxibustion
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hand acupuncture
Number of subjects: 10

Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 10
Study: 15181138

Group type: EXPERIMENTAL
Intervention: Shifting emission images after initial scans
Number of subjects: 1177

Group type: COMPARATOR
Intervention: Initial MAC scan followed by emission scans
Number of subjects: 1177

Group type: EXPERIMENTAL
Intervention: Diaphragm displacement measurement
Number of subjects: 1177

Group type: EXPERIMENTAL
Intervention: Quantitative misregistration assessment
Number of subjects: 1177
Study: 12078910

Group type: EXPERIMENTAL
Intervention: Early complete response (ECR) patients after initial cycles of chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Shortened treatment in ECR patients (randomized Swedish trial)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ECR patients receiving only six cycles (EORTC 20884 study)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anthracyclines plus alkylating agents in children who failed to reach ECR (French MDH 90 trial)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Involved field radiotherapy for patients who failed to reach ECR (EORTC 20884 study)
Number of subjects: 0
Study: 9621488

Group type: EXPERIMENTAL
Intervention: Carboplatin (100 mg/m2 at 7 and 21 days) with 148 MBq 89Sr
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cisplatin (50 mg/m2 in two administrations) with 148 MBq 89Sr
Number of subjects: 30

Group type: COMPARATOR
Intervention: 89Sr alone
Number of subjects: 30

Group type: COMPARATOR
Intervention: 89Sr + placebo
Number of subjects: 30
Study: 8576718

Group type: EXPERIMENTAL
Intervention: Prompting device available (experimental group)
Number of subjects: 39

Group type: COMPARATOR
Intervention: No prompting device available (control group)
Number of subjects: 39
Study: 2671617

Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diuretic therapy
Number of subjects: 0
Study: 62265

Group type: EXPERIMENTAL
Intervention: Total nodal irradiation (T.N.I.)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Combination chemotherapy (MOPP: mustine hydrochloride, vincristine, procarbazine, and prednisone)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Combination chemotherapy (MOPP)
Number of subjects: 117
Study: 28834381

Group type: EXPERIMENTAL
Intervention: Salbutamol (n = 84)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo (n = 19)
Number of subjects: 103
Study: 25993549

Group type: EXPERIMENTAL
Intervention: Multifaceted workplace intervention (participatory ergonomics, physical training, CBT)
Number of subjects: 594
Study: 23287638

Group type: EXPERIMENTAL
Intervention: α-tocopherol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20082117

Group type: EXPERIMENTAL
Intervention: Ipilimumab plus DTIC
Number of subjects: 72

Group type: COMPARATOR
Intervention: Ipilimumab alone
Number of subjects: 72
Study: 19920428

Group type: EXPERIMENTAL
Intervention: US-guided FNB
Number of subjects: 107

Group type: COMPARATOR
Intervention: US-guided FNB with nerve stimulation (USNS)
Number of subjects: 107

Group type: COMPARATOR
Intervention: USNS
Number of subjects: 107
Study: 17305788

Group type: EXPERIMENTAL
Intervention: AQUACEL Hydrofiber dressings containing ionic silver (AQAg)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Algosteril calcium alginate (CA) dressings
Number of subjects: 134
Study: 15633440

Group type: EXPERIMENTAL
Intervention: Primary angioplasty (PCI)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Thrombolytic therapy (TT)
Number of subjects: 21
Study: 11137283

Group type: EXPERIMENTAL
Intervention: 10 mg ritanserin for 4 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 80
Study: 9392620

Group type: EXPERIMENTAL
Intervention: Continuous-infusion BSO alone
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: BSO plus melphalan (15 mg/m2)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: BSO plus melphalan
Number of subjects: 21

Group type: COMPARATOR
Intervention: BSO
Number of subjects: 21
Study: 7639365

Group type: EXPERIMENTAL
Intervention: Epidural fentanyl
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Epidural clonidine
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combination of fentanyl and clonidine
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 90
Study: 30674430

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% (GPEC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline (GC)
Number of subjects: 30
Study: 27890777

Group type: EXPERIMENTAL
Intervention: Psychological wellbeing assessed with the Depression Anxiety and Stress Scale (DASS)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Cognitive function assessed using the Delayed Matching to Samples (DMS) test from the Cambridge Neuropsychological Test Automated Battery (CANTAB)
Number of subjects: 41
Study: 25762426

Group type: EXPERIMENTAL
Intervention: Relaxation and guided imagery
Number of subjects: 37

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 37
Study: 23415313

Group type: EXPERIMENTAL
Intervention: TAC/MMF
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: TAC/SRL
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: SRL/MMF
Number of subjects: 78

Group type: COMPARATOR
Intervention: TAC/MMF vs TAC/SRL
Number of subjects: 78

Group type: COMPARATOR
Intervention: TAC/MMF vs SRL/MMF
Number of subjects: 78

Group type: COMPARATOR
Intervention: TAC/SRL vs SRL/MMF
Number of subjects: 78

Group type: COMPARATOR
Intervention: TAC/SRL vs TAC/MMF
Number of subjects: 78

Group type: COMPARATOR
Intervention: SRL/MMF vs TAC/MMF
Number of subjects: 78
Study: 21154196

Group type: EXPERIMENTAL
Intervention: Oxytocin (OT) infused at a constant rate of 2 mIU/ml from -15 to 60 min before insulin administration
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 17947611

Group type: EXPERIMENTAL
Intervention: Clarithromycin (500 mg twice daily)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 16481458

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) training
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 19
Study: 14564551

Group type: EXPERIMENTAL
Intervention: Modified angiographic protocol (127 patients); 20 mL iodinated contrast, digital subtraction fluoroscopy for 60 sec.
Number of subjects: 391

Group type: COMPARATOR
Intervention: Standard completion angiograms (264 patients).
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Modified protocol; postoperative CT scans at 6 months.
Number of subjects: 391

Group type: COMPARATOR
Intervention: Standard protocol; postoperative CT scans at 6 months.
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Modified protocol; postoperative CT scans at 12 months.
Number of subjects: 391

Group type: COMPARATOR
Intervention: Standard protocol; postoperative CT scans at 12 months.
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Overall morbidity rate.
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Perioperative mortality rate.
Number of subjects: 391
Study: 10625720

Group type: EXPERIMENTAL
Intervention: Clomethiazole (75 mg/kg intravenous infusion for 24 hours)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Clomethiazole
Number of subjects: 95
Study: 9184976

Group type: EXPERIMENTAL
Intervention: Erbe electrocautery device
Number of subjects: 57

Group type: COMPARATOR
Intervention: Conventional electrocautery
Number of subjects: 57
Study: 1590670

Group type: EXPERIMENTAL
Intervention: Oral riboflavin therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (not receiving riboflavin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (riboflavin and placebo)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Riboflavin supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Riboflavin deficiency
Number of subjects: 0
Study: 2859871

Group type: EXPERIMENTAL
Intervention: Adimolol 25 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Adimolol 600 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Adimolol 400 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Labetalol 800 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Labetalol 400 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 29678756

Group type: EXPERIMENTAL
Intervention: D&C plus NCH gel application (NCH gel group)
Number of subjects: 300

Group type: COMPARATOR
Intervention: D&C alone (control group)
Number of subjects: 300
Study: 30189776

Group type: EXPERIMENTAL
Intervention: Ultra-narrow sterile exsanguination tourniquet (SET)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Wide contoured pneumatic tourniquet (PT)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: SET
Number of subjects: 58

Group type: COMPARATOR
Intervention: PT
Number of subjects: 58
Study: 27626473

Group type: EXPERIMENTAL
Intervention: LDE-paclitaxel (175 mg/m2, intravenous administration, 3/3 weeks for 6 cycles)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (untreated patients)
Number of subjects: 17
Study: 25197811

Group type: EXPERIMENTAL
Intervention: Melatonin (5 mg) in the morning
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Melatonin (5 mg) in the evening
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 22116977

Group type: EXPERIMENTAL
Intervention: Collaborative care (n = 65)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Usual care (n = 61)
Number of subjects: 126
Study: 20453053

Group type: EXPERIMENTAL
Intervention: Communication and stress management skills training programme
Number of subjects: 96
Study: 17664376

Group type: EXPERIMENTAL
Intervention: Pravastatin 20 or 40 mg, depending on age, continued after a previous placebo-controlled study for an average treatment period of 4.5 years.
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Pravastatin treatment
Number of subjects: 186
Study: 16236186

Group type: EXPERIMENTAL
Intervention: Haem iron preparation
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Ferrous sulphate (FeSO4)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Beans-only (control)
Number of subjects: 110
Study: 12473512

Group type: EXPERIMENTAL
Intervention: Fluorouracil, docetaxel (in patients who have already received paclitaxel), vinorelbine, mitomycin c
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel oral therapies
Number of subjects: 0
Study: 10209080

Group type: EXPERIMENTAL
Intervention: Ephedrine (50 mg thrice daily)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 7609291

Group type: EXPERIMENTAL
Intervention: Rectal diclofenac 50 mg plus continuous epidural infusion with buprenorphine and bupivacaine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Continuous epidural infusion with buprenorphine and bupivacaine
Number of subjects: 80
Study: 2222132

Group type: EXPERIMENTAL
Intervention: Phenelzine sulfate
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Imipramine hydrochloride
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 318971

Group type: EXPERIMENTAL
Intervention: Fosfomycin 2 g daily in four divided doses for 28 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 31505025

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 31021036

Group type: EXPERIMENTAL
Intervention: facilitated subcutaneous immunoglobulin (fSCIG)
Number of subjects: 20

Group type: COMPARATOR
Intervention: conventional subcutaneous immunoglobulin (cSCIG)
Number of subjects: 20
Study: 27592520

Group type: EXPERIMENTAL
Intervention: Music therapy (listening to music three days a week for 8 weeks)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 64
Study: 25613721

Group type: EXPERIMENTAL
Intervention: IIV4-ID
Number of subjects: 3355

Group type: COMPARATOR
Intervention: IIV3-ID (licensed)
Number of subjects: 3355

Group type: COMPARATOR
Intervention: IIV3-ID (investigational)
Number of subjects: 3355

Group type: COMPARATOR
Intervention: IIV3-ID (licensed and investigational)
Number of subjects: 3355
Study: 23917748

Group type: EXPERIMENTAL
Intervention: 400 ppb ozone
Number of subjects: 10

Group type: COMPARATOR
Intervention: filtered air
Number of subjects: 10
Study: 21792546

Group type: EXPERIMENTAL
Intervention: Paraprofessional home visitation and parent-infant groups for 1 year
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control group) with monthly social work contact
Number of subjects: 0
Study: 19873915

Group type: EXPERIMENTAL
Intervention: Acupuncture at local points of eye (Jingming (BL 1), Tongziliao (GB 1), Shangming (Extra))
Number of subjects: 100

Group type: COMPARATOR
Intervention: Oral administration of Methycobal and Vitamin B1 (medication group)
Number of subjects: 100
Study: 17878129

Group type: EXPERIMENTAL
Intervention: Breast Cancer Education Intervention (BCEI) delivered in three face‐to‐face sessions and five monthly follow‐up sessions (three by telephone and two in person)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Wait control group receiving four monthly attention control telephone calls and the BCEI at month 6
Number of subjects: 256
Study: 14679271

Group type: EXPERIMENTAL
Intervention: Healthy Steps Program
Number of subjects: 5565
Study: 10690889

Group type: EXPERIMENTAL
Intervention: GH treatment group A (4 IU/m2 x day)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: GH treatment group B (4 IU/m2 x day for the first year, then 6 IU/m2 x day)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: GH treatment group C (4 IU/m2 x day for the first year, 6 IU/m2 x day for the second year, then 8 IU/m2 x day)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: GH treatment group C1 (7-year data from group C)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: GH treatment (mean duration 85.3 months)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: GH treatment
Number of subjects: 68
Study: 9347244

Group type: EXPERIMENTAL
Intervention: Acarbose 100 mg t.i.d.
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 8360391

Group type: EXPERIMENTAL
Intervention: Anthelmintic treatment (Oxantel-Pyrantel; Quantrel) for 22 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (children who declined treatment)
Number of subjects: 0
Study: 2875439

Group type: EXPERIMENTAL
Intervention: Cognitive group: systematic desensitization (SYS DENS)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cognitive group: sensory description (SEN DESC)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cognitive group: sensory transformation (ST)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cognitive group: modeling (M)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cognitive group: relaxation (R)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combined cognitive groups: SYS DENS, SEN DESC, and ST
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combined cognitive groups: SEN DESC, ST, and R
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combined cognitive groups: SEN DESC, R, ST, and Demerol
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Pharmacologic group: expected Demerol
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Pharmacologic group: did not expect Demerol
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Pharmacologic group: placebo
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group: no treatment
Number of subjects: 120
Study: 30817560

Group type: EXPERIMENTAL
Intervention: NRP Prompt (interactive mobile application providing audiovisual prompts)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Standard visual aids with NRP Prompt
Number of subjects: 39

Group type: COMPARATOR
Intervention: Visual aids only (control)
Number of subjects: 39
Study: 30572554

Group type: EXPERIMENTAL
Intervention: Rational Emotive Digital Storytelling Intervention (REDStory)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 0
Study: 26735263

Group type: EXPERIMENTAL
Intervention: PSA featuring real person
Number of subjects: 4

Group type: COMPARATOR
Intervention: PSA featuring actor
Number of subjects: 4
Study: 25169652

Group type: EXPERIMENTAL
Intervention: Pacifier use
Number of subjects: 30

Group type: COMPARATOR
Intervention: No pacifier use (Control)
Number of subjects: 30
Study: 20830502

Group type: EXPERIMENTAL
Intervention: Vandetanib (100 mg once daily) plus docetaxel (100 mg/m² IV every 21 days)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo plus docetaxel (100 mg/m² IV every 21 days)
Number of subjects: 64
Study: 19459523

Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors (PPI)
Number of subjects: 569

Group type: COMPARATOR
Intervention: Histamine-2 receptor antagonists (H2RA)
Number of subjects: 569
Study: 17240233

Group type: EXPERIMENTAL
Intervention: Local anesthesia (1% lidocaine)
Number of subjects: 204

Group type: COMPARATOR
Intervention: No local anesthesia
Number of subjects: 204
Study: 15562020

Group type: EXPERIMENTAL
Intervention: 25 mg testosterone enanthate weekly
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 50 mg testosterone enanthate weekly
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 125 mg testosterone enanthate weekly
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 300 mg testosterone enanthate weekly
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 600 mg testosterone enanthate weekly
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (young men, 19-35 years)
Number of subjects: 60
Study: 12244484

Group type: EXPERIMENTAL
Intervention: Medium-molecular-weight heparin (MMWH)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Low-molecular-weight heparin (enoxaparin)
Number of subjects: 16
Study: 10443094

Group type: EXPERIMENTAL
Intervention: Xylocaine injection at the gastrocnemius trigger point (TrP)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Oral quinine sulfate 300 mg
Number of subjects: 24
Study: 7603215

Group type: EXPERIMENTAL
Intervention: Ganciclovir (6 mg/kg body weight per day intravenously from postoperative day 1 to day 30, then 6 mg/kg per day Monday through Friday until day 100)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Acyclovir (10 mg/kg intravenously every 8 h from postoperative day 1 to day of discharge, then 800 mg orally four times a day until day 100)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Ganciclovir
Number of subjects: 250

Group type: COMPARATOR
Intervention: Acyclovir
Number of subjects: 250
Study: 1695049

Group type: EXPERIMENTAL
Intervention: Cisplatin (DDP) alone
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Cisplatin (DDP) in combination with Adriamycine (ADM) and Cyclophosphamid (CTX)
Number of subjects: 173